DERM — Journey Medical Cashflow Statement
0.000.00%
- $174.29m
- $175.48m
- $61.86m
Annual cashflow statement for Journey Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -44 | -29.6 | -3.85 | -14.7 | -11.4 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 23.1 | 5.63 | 6.98 | 5.89 | 6.63 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 14.7 | 6.19 | -1.66 | -3.77 | -11.9 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Cash from Operating Activities | -2.18 | -13.5 | 5.24 | -9.13 | -12.4 |
| Capital Expenditures | -10 | -20 | -5 | -15 | — |
| Purchase / Acquisition of Intangibles | |||||
| Cash from Investing Activities | -10 | -20 | -5 | -15 | — |
| Financing Cash Flow Items | -3.55 | -0.585 | 4.02 | 7.83 | 16.3 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 53 | 16.5 | -4.8 | 17 | 16.2 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 40.8 | -17.1 | -4.56 | -7.13 | 3.79 |